We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Epidermal Growth Factor Receptor (EGFR) Antibodies|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This EGFR antibody is un-conjugated Alternatives|
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), ELISA, Western Blotting (WB)
|7 references available|
|Supplier||Log in to see|
Product Details anti-EGFR AntibodyTarget Details EGFR Application Details Handling References for anti-EGFR antibody (ABIN967602) Images
|Cross-Reactivity||Mouse (Murine), Rat (Rattus)|
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to us for technical protocols.
|Purification||The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.|
|Immunogen||Phosphorylated Human EGF Receptor Peptide|
Target Details EGFRProduct Details anti-EGFR Antibody Application Details Handling References for anti-EGFR antibody (ABIN967602) Images back to top
|Alternative Name||EGF Receptor (EGFR Antibody Abstract)|
Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. In addition, c-Src-dependent phosphorylations at other sites, such as tyrosine 845 (Y845) in the kinase domain, regulate the receptor's kinase activity. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The 12A3 monoclonal antibody recognizes the phosphorylated Y845 in the protein tyrosine kinase domain of human EGFR.
|Molecular Weight||175 kDa|
|Pathways||NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation|
Application DetailsProduct Details anti-EGFR Antibody Target Details EGFR Handling References for anti-EGFR antibody (ABIN967602) Images back to top
Related Products: ABIN967389
|Restrictions||For Research Use only|
HandlingProduct Details anti-EGFR Antibody Target Details EGFR Application Details References for anti-EGFR antibody (ABIN967602) Images back to top
|Buffer||Aqueous buffered solution containing ≤0.09 % sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store undiluted at 4°C.|
References for anti-EGFR antibody (ABIN967602)Product Details anti-EGFR Antibody Target Details EGFR Application Details Handling Images back to top
|Product cited in:||
Hristozova, Konschak, Budach, Tinhofer: "A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers." in: Cytometry. Part A : the journal of the International Society for Analytical Cytology, Vol. 81, Issue 6, pp. 489-95, 2012
Boerner, Demory, Silva, Parsons: "Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II." in: Molecular and cellular biology, Vol. 24, Issue 16, pp. 7059-71, 2004
Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, 2003
Moro, Dolce, Cabodi, Bergatto, Boeri Erba, Smeriglio, Turco, Retta, Giuffrida, Venturino, Godovac-Zimmermann, Conti, Schaefer, Beguinot, Tacchetti, Gaggini, Silengo, Tarone, Defilippi: "Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines." in: The Journal of biological chemistry, Vol. 277, Issue 11, pp. 9405-14, 2002
Wu, Graves, Gill, Parsons, Samet: "Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation." in: The Journal of biological chemistry, Vol. 277, Issue 27, pp. 24252-7, 2002
Olayioye, Neve, Lane, Hynes: "The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, 2000
Biscardi, Maa, Tice, Cox, Leu, Parsons: "c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function." in: The Journal of biological chemistry, Vol. 274, Issue 12, pp. 8335-43, 1999
ImagesProduct Details anti-EGFR Antibody Target Details EGFR Application Details Handling References for anti-EGFR antibody (ABIN967602) back to top